Nuclear factor-κB in cancer development and progression

Nature

Volumn 441, Issue 7092, 2006, Pages 431-436

  Karin, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENETIC ENGINEERING; IMMUNOLOGY; ONCOLOGY; PATIENT TREATMENT;

MALIGNANT CELLS; NUCLEAR FACTOR; TRANSCRIPTION FACTORS;

TUMORS;

ANTIBIOTIC AGENT; CYCLIN D1; FLICE INHIBITORY PROTEIN; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN BCL 10; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

CANCER; CHEMOTHERAPY; IMMUNE RESPONSE; TUMOR;

APOPTOSIS; B LYMPHOCYTE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER PREVENTION; CARCINOGENESIS; CELL STIMULATION; CHROMOSOME TRANSLOCATION; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL DISEASE; ENZYME ACTIVATION; GENE EXPRESSION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LYMPHOMA; MOUSE STRAIN; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; STOMACH CANCER; STOMACH CARCINOGENESIS; TISSUE NECROSIS; ULCERATIVE COLITIS; ANIMAL; DISEASE COURSE; DRUG ANTAGONISM; LIVER TUMOR; METABOLISM; NEOPLASM; PATHOLOGY; SKIN TUMOR;

ANIMALS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; LIVER NEOPLASMS; NEOPLASMS; NF-KAPPA B; SKIN NEOPLASMS;

EID: 33745298519     PISSN: 00280836     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/nature04870     Document Type: Review

References (70)

1. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001).
2. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
3. Kuper, H., Adami, H. O. & Trichopoulos, D. Infections as a major preventable cause of human cancer. J. Intern. Med. 248, 171-183 (2000).
4. Roder, D. M. The epidemiology of gastric cancer. Gastric Cancer 5 (Suppl.1), 5-11 (2002).
5. Ekbom, A. Risk of cancer in ulcerative colitis. J. Gastrointest. Surg. 2, 312-313 (1998).
6. Dhala, A., Pinsker, K. & Prezant, D. J. Respiratory health consequences of environmental tobacco smoke. Med. Clin. North Am. 88, 1535-1552, xi (2004).
7. Greten, F. R. & Karin, M. NF-κB: linking inflammation and immunity to cancer development and progression. Nature Rev. Immunol. 5, 749-759 (2005).
8. Balkwill, F., Charles, K. A. & Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217 (2005).
9. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
10. Li, Q., Withoff, S. & Verma, I. M. Inflammation-associated cancer: NF-κB is the lynchpin. Trends Immunol. 26, 318-325 (2005).
11. Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-κB in cancer: from innocent bystander to major culprit. Nature Rev. Cancer 2, 301-310 (2002).
12. Gilmore, T. D. The Re1/NF-κB/IκB signal transduction pathway and cancer. Cancer Treat. Res. 115, 241-265 (2003).
13. Medzhitov, R. Toll-like receptors and innate immunity. Nature Rev. Immunol. 1, 135-145 (2001).
14. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
15. Nizet, V., Lawrence, T. & Karin, M. Innate immunity gone awry: mechanisms linking microbial infections to chronic inflammatory disorders and cancer. Cell 124, 823-835 (2006).
16. Li, Q. & Verma, I. M. NF-κB regulation in the immune system. Nature Rev. Immunol. 2, 725-734 (2002).
17. Sun, J. et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J. Natl Cancer Inst. 97, 525-532 (2005).
18. El-Omar, E. M. et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404, 398-402 (2000).
19. Arnott, C. H. et al. Tumour-necrosis factor-α mediates tumour promotion via a PKCα-and AP-1-dependent pathway. Oncogene 21, 4728-4738 (2002).
20. Lind, M. H. et al. Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-κ inhibition. Proc. Natl Acad. Sci. USA 101, 4972-4977 (2004).
21. Pikarsky, E. et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461-466 (2004).
22. Balkwill, F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 13, 135-141 (2002).
23. Oshima, M., Oshima, H., Matsunaga, A. & Taketo, M. M. Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia caused by tumor necrosis factor-α-dependent inflammation in cyclooxygenase-2/ microsomal prostaglandin E synthase-1 transgenicmice. Cancer Res. 65, 9147-9151 (2005).
24. Liu, Z.-G., Hu, H., Goeddel, D. V. & Karin, M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis, while NF-κB activation prevents cell death. Cell 87, 565-576 (1996).
25. Beg, A. A. & Baltimore, D. An essential role for NF-κB in preventing TNF-α induced cell death. Science 274, 782-784 (1996).
26. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R. & Verma, I. M. Suppression of TNFα-induced apoptosis by NF-κB. Science 274, 787-789 (1996).
27. Wang, C.-Y., Mayo, M. W. & Baldwin, A. S. Jr. TNF-α and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274, 784-787 (1996).
28. Makris, C. et al. Female mice heterozygous for IKKγ/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol. Cell 5, 969-979 (2000).
29. Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K. & Tschopp, J. NF-κ signals induce the expression of c-FLIP. Mol. Cell. Biol. 21, 5299-5305 (2001).
30. Karin, M. & Lin, A. NF-κB at the crossroads of life and death. Nature Immunol. 3, 221-227 (2002).
31. Danial, N. N. & Korsmeyer, S. J. Cell death: critical control points. Cell 116, 205-219 (2004).
32. Lavon, I. et al. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-κB activation. Nature Med. 6, 573-577 (2000).
33. Chen, L. W. et al. The two faces of IKK and NF-κB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nature Med. 9, 575-581 (2003).
34. Okayasu, I., Ohkusa, T., Kajiura, K., Kanno, J. & Sakamoto, S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39, 87-92 (1996).
35. Greten, F. R. et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296 (2004).
36. Becker, C. et al. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21, 491-501 (2004).
37. Mauad, T. H. et al. Mice with homozygous disruption of the mdr2P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 145, 1237-1245 (1994).
38. Zucca, E., Bertoni, F., Roggero, E. & Cavalli, F. The gastric marginal zone B-cell lymphoma of MALT type. Blood 96, 410-419 (2000).
39. Ruland, J. et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-κB and neural tube closure. Cell 104, 33-42 (2001).
40. Lucas, P. C. et al. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-κB signaling pathway. J. Biol. Chem. 276, 19012-19019 (2001).
41. Thome, M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nature Rev. Immunol. 4, 348-359 (2004).
42. van Hogerlinden, M., Rozell, B. L., Ahrlund-Richter, L. & Toftgard, R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-κB signaling. Cancer Res. 59, 3299-3303 (1999).
43. van Hogerlinden, M., Auer, G. & Toftgard, R. Inhibition of Rel/nuclear factor-κB signaling in skin results in defective DNA damage-induced cell cycle arrest and Ha-ras- and p53-independent tumor development. Oncogene 21, 4969-4977 (2002).
44. Dajee, M. et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421, 639-643 (2003).
45. Zhang, J. Y., Green, C. L., Tao, S. & Khavari, P. A. NF-κB RelA opposes epidermal proliferation driven by TNFR1 and JNK. Genes Dev. 18, 17-22 (2004).
46. Karin, M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270, 16483-16486 (1995).
47. Kamata, H. et al. Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120, 649-661 (2005).
48. Pham, C. G. et al. Ferritin heavy chain upregulation by NF-κB inhibits TNFa-induced apoptosis by suppressing reactive oxygen species. Cell 119, 529-542 (2004).
49. Maeda, S., Kamata, H., Luo, J. L., Leffert, H. & Karin, M. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocardnogenesis. Cell 121, 977-990 (2005).
50. Chang, L. et al. The E3 ubiquitin ligase itch couples JNK activation to TNFα-induced cell death by inducing c-FLIP(L) turnover. Cell 124, 601-613 (2006).
51. Park, J. S. et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370-7377 (2004).
52. Holla, V. R. et al. Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer. J. Biol. Chem. 280, 476-483 (2005).
53. Sparmann, A. & Bar-Sagi, D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447-458 (2004).
54. Garkavtsev, I. et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428, 328-332 (2004).
55. Joyce, D. et al. NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 12, 73-90 (2001).
56. Cao, Y. et al. IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107, 763-775 (2001).
57. Luo, J. L., Maeda, S., Hsu, L. C., Yagita, H. & Karin, M. Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 6, 297-305 (2004).
58. Karin, M., Yamamoto, Y. & Wang, Q. M. The IKK NF-κ system: a treasure trove for drug development. Nature Rev. Drug Discov. 3, 17-26 (2004).
59. Ghosh, S. & Karin, M. Missing pieces in the NF-κB puzzle. Cell 109 (suppl.), S81-S96 (2002).
60. Gilmore, T. D. The Rel/NF-κB signal transduction pathway: introduction. Oncogene 18, 6842-6844 (1999).
61. Rothwarf, D. M. & Karin, M. The NF-κB activation pathway: a paradigm in information transfer from membrane to nucleus. Sci. STKE 1999, RE1 (1999).
62. Karin, M. & Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621-663 (2000).
63. Werner, S. L., Barken, D. & Hoffmann, A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 309, 1857-1861 (2005).
64. Park, J. M. et al. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis - CREB and NF-κB as key regulators. Immunity 23, 319-329 (2005).
65. Covert, M. W., Leung, T. H., Gaston, J. E. & Baltimore, D. Achieving stability of lipopolysaccharide-induced NF-κB activation. Science 309, 1854-1857 (2005).
66. Bonizzi, G. & Karin, M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25, 280-288 (2004).
67. Senftleben, U. et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 293, 1495-1499 (2001).
68. Neri, A. et al. B-cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell 67, 1075-1087 (1991).
69. Demicco, E. G. et al. RelB/p52 NF-κB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IκB-α expression and promote carcinogenesis of the mammary gland. Mol. Cell. Biol. 25, 10136-10147 (2005).
70. Kato, T. Jr., Delhase, M., Hoffmann, A. & Karin, M. CK2 Is a c-terminal IκB kinase responsible for NF-κB activation during the UV response. Mol. Cell 12, 829-839 (2003).